Pharma firm Lupin has received approval from the US health regulator to market its Desoximetasone ointment, used for providing relief from inflammation and itching in a skin disease.
The company has received final approval to market its Desoximetasone ointment USP, 0.05 per cent from the United States Food & Drug Administration (USFDA), Lupin said in a filing to BSE.
The product filing is from the company’s Pithampur manufacturing facility, it added.
The Mumbai-based company’s product is the generic version of Taro Pharms North’s Topicort ointment in the same strength.
According to IMS, MAT September 2016 sales data, Topicort had US sales of $12.1 million, Lupin said.
The ointment is “indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,” it added.
The Lupin stock was trading marginally up at Rs 1,493 in afternoon on the BSE.